Purpose: Levetiracetam is one of the most widely used antiepileptic drugs, but the evidence related to the safety of substitution from brand name to generic levetiracetam is scarce. The present study evaluated the risk of increased frequency of seizures after replacement of a brand-name levetiracetam with a generic product. Methods: We enrolled patients with epilepsy who were treated with branded levetiracetam for at least 6 months of sustained use. Patients were advised to switch to the generic levetiracetam. We analyzed data from 6 months before, to 6 months after, generic substitution. Increased seizure frequency was defined as a≥ 50% increase in seizure frequency after conversion date compared with seizure frequency before the conversion date. We analyzed changes in seizure frequency and performed subgroup analysis according to changes in seizure frequency. Results: We analyzed 148 epilepsy patients. Among the 148 patients, 109 (73.6%) were seizure-free before substitution and 105 patients remained seizure-free after switching. After generic substitution, an increased seizure frequency was noted in seven patients (4.7%), and a decreased seizure frequency was noted in 10 (6.8%). Patients with decreased seizure frequency were significantly younger (p = 0.035) than those with an unchanged seizure frequency. Conclusion: This study suggests that the risk of increased seizure frequency after generic substitution was minimal. The generic substitution of levetiracetam was generally safe, although larger prospective studies are warranted to corroborate our findings.
T replacement of a brand-name LEV with a generic product.
Methods

Subjects
Patients aged at least 16 years with epilepsy who were treated with LEV between March and September 2015 were enrolled in this study. They were recruited from the tertiary outpatient epilepsy clinic at the Department of Neurology, Pusan National University Hospital, Republic of Korea. Patients were included if they had converted from brand to generic LEV, had 6 or more months of sustained LEV use, had been receiving the same dose of AED including LEV for at least 6 months prior to generic substitution, and if their epilepsy duration was at least 1 year. Subjects were excluded if they had severe medical and psychiatric disorders and/or if their seizure frequency could not be quantified. All of the patients included in the study were regularly monitored by one of two physicians, both co-authors of this study. This study was approved by the Institutional Review Board of Pusan National University Hospital.
Assessment
A standardized data form was developed, and data were obtained retrospectively from individual patient medical records. Variables included in the database were age, sex, age at onset, classification of epilepsy, number and dose of concomitant administered AEDs, the dose of LEV, seizure frequency, magnetic resonance imaging (MRI) results, and electroencephalographic findings. Epilepsy was classified using the International League Against Epilepsy classification [24] .
We analyzed data from 6 months before, to 6 months after substitution. The interval between visits was typically 3 months. The first date a patient received a prescription for generic LEV was considered their conversion date. Seizure frequency was reported by the patients and their family members. Seizure frequency was determined by seizure number during the 6 months before and after conversion date. Seizure freedom was defined by a seizure-free status during the 6 months before and after conversion date, respectively. An increased frequency of seizures was defined as a ≥ 50% increase in seizure frequency after conversion date from the seizure frequency before conversion date. We also registered potential adverse events.
Statistical analysis
Statistical analysis was performed using SPSS 22.0 (IBN corp., Armonk, NY, USA). Quantitative variables are expressed as the median with interquartile range (IQR) due to the non-parametric distribution. Qualitative variables were characterized by numbers and percentages. Wilcoxon signed-rank test was used to examine the difference between medians of seizure frequency before and after generic substitution. Chisquared test (or Fisher exact test, where appropriate) and KruskalWallis H test were used to assess the significance of the differences between subgroups according to changes in seizure frequency. Bonferroni's correction was applied to the post hoc analysis of betweengroup or within-group comparisons. P < 0.05 was considered statistically significant.
Results
Patient characteristics (Table 1)
Between March and September 2015, 239 patients with epilepsy received at least one prescription for LEV. Of this group, 154 epilepsy patients met the inclusion criteria, but six patients were lost to followup. A total of 148 subjects was included in the final study cohort. Patients involved in this study had idiopathic epilepsy (10 patients, 6 .8%), cryptogenic epilepsy (64 patients, 43.2%), or symptomatic epilepsy (74 patients, 50%). The median seizure frequency of all seizure types before conversion date was 0 (IQR 0-1) for 6 months. Sixty-six patients (44.6%) were on branded-LEV as monotherapy, and 82 patients (55.4%) as polytherapy in association with one or more other AEDs. The median LEV dose was 1000 mg/day.
Seizure freedom
Initially, 109 patients (73.6%) were seizure-free during the 6 months before generic substitution. Seizure freedom was maintained in 105 patients (96.3%) and seizures occurred in four patients (3.7%) during the 6 months after substitution. Of the 39 patients who initially had seizures before substitution, eight patients were seizure-free after generic substitution. Finally, 113 patients (76.4%) were seizure-free at 6 months after substitution (Fig. 1 ).
Changes in seizure frequency
The baseline median frequency of all seizure types before conversion date was 0 (IQR 0-1) for 6 months. The median seizure frequency after substitution was the same as frequency before substitution (0 for 6 months, IQR 0-1). The difference between median seizure frequency associated with the original and generic brands was not significant (P = 0.886).
Of 66 patients with LEV as monotherapy, only one patient (1.5%) had an increased seizure frequency (≥50% of the baseline frequency) and two patients (3.0%) had a decreased seizure frequency (≤50% of the baseline frequency). Of 82 patients with LEV as polytherapy, six patients had an increased seizure frequency and eight patients had a decreased seizure frequency. Overall, the increased frequency of seizures was noted in seven patients (4.7%) during the 6 months after substitution. The dose of the generic LEV was increased in four patients. The other three patients had a breakthrough seizure without taking AEDs and were instructed to take medication regularly. Ten patients had a decreased seizure frequency (6.8%) (Fig. 2) .
Characteristics of subgroups according to changes in seizure frequency (Table 2)
The subgroup that experienced increased seizure frequency comprised three men and four women. Six patients had focal epilepsy and one patient had generalized epilepsy. One patient was treated with LEV monotherapy, three with LEV and other AEDs, and three with LEV and more than two other AEDs. Medications used in polytherapy included lamotrigine (n = 3), carbamazepine (n = 3), valproate (n = 2), and topiramate (n = 1) . All patients with decreased seizure frequency had focal epilepsy. Two patients were treated with LEV monotherapy, three received two AEDs, and five received more than three AEDs. Other AEDs included carbamazepine (n = 4), topiramate (n = 3), oxcarbazepine (n = 2), lamotrigine (n = 2), and valproate (n = 1).
Age (P = 0.04) and seizure frequency at baseline (P < 0.001) were significantly different according to changes in seizure frequency. Based on post hoc analysis, the group of patients with decreased seizure fre- 
Discussion
In this retrospective study, we have evaluated the risk of generic substitution of LEV, focusing on breakthrough seizures and the increased frequency of seizures after replacement in 148 patients with epilepsy. The proportion of seizure-free patients was similar before (73.6%) and after (76.4%) substitution. During the 6 months after substitution, seven patients (4.7%) had an increased frequency of seizures with ≥50% of baseline seizure frequency, whereas 10 patients (6.8%) had a decreased seizure frequency. A major strength of our study is that we investigated the effect of generic substitution of LEV in patients with epilepsy without changes in the type or dose of antiepileptic drugs for 6 months before substitution. In addition, we analyzed patients with LEV monotherapy and seizure freedom, and observed that LEV substitution was generally safe in patients with wellcontrolled epilepsy.
Generic prescription substantially reduces the costs of treatment and plays an important role in patient adherence due to the lower price compared to that of branded products [4] [5] [6] [7] [8] . Generic products must demonstrate bioequivalence, which can be determined when the 90% CI for the means of the ratios of Cmax and AUC fall within 80-125% [2, 25, 26] . Clinical evidence suggests that a difference less than 20% is not clinically significant [3] . Nevertheless, significant controversy exists regarding generic substitution, particularly for AEDs [10] [11] [12] [13] [14] . Several studies reported that switchback rates are substantially higher for AEDs than for non-AEDs [18, 27] . The switchback rates were 12.9-27.5% for lamotrigine, 30.9% for gabapentin, and 20.9% for valproate; while non-AEDs such as statins and selective serotonin reuptake inhibitors had low switchback rates (1.5% and 2.9%, respectively) [18, 27] . AEDs have numerous pharmacokinetic factors that may increase the probability of problems associated with generic substitution [14] . Small changes in AED plasma concentrations can impact seizure control as well as toxicity in patients with epilepsy [15] [16] [17] . Clinicians are concerned about substituting AEDs, especially in wellcontrolled patients, as even a single breakthrough seizure may have severe financial and social consequences, such as loss of driving license, loss of employment, and/or injuries [28] .
LEV is a relatively new and widely-used AED that is approved for the treatment of partial or generalized epilepsy in children and adults [19, 29] . LEV is a highly soluble and permeable compound drug with a linear pharmacokinetic profile [30] . A study examined the serum levels of LEV in 33 patients on stable treatment with branded LEV who either continued with branded LEV or were switched to a generic LEV. The generic LEV was determined to be bioequivalent to brand-name LEV [31] . Another study showed that the fluctuation of LEV serum concentrations with branded and generic LEV was equal, and within-subject variability was much larger than the differences between brands [32] . In our present study, the number of patients with increased seizure frequency (seven patients, 4.7%) were similar to the number of patients with decreased seizure frequency (10 patients, 6.8%). Furthermore, the seizure-free rate of branded (109 patients, 73.6%) and generic LEV (113 patients, 76.4%) was similar. These data suggest that substitution from branded LEV to a generic product is not associated with any significant change in seizure frequency. These results contrast with the findings of a previous study, which showed a high switchback rate [21] . In this earlier study, among 260 patients prescribed generic LEV, 105 (42.9%) were switched back to brand-name LEV for 18 months. Reasons for switchback included an increase in seizure frequency on generics (48 patients, 19.6%) and adverse effects that were not experienced on the branded LEV (eight patients, 3.3%). The reasons of switchback to branded LEV in the remaining 49 patients were not described. Two other studies on LEV generic substitution reported that seizure frequency remained unchanged when branded LEV was substituted with a generic equivalent, similar to our results [22, 23] . A prospective study of 59 patients who were switched from branded to generic LEV reported that only two patients (3.4%) had increased seizure frequency, and there was no significant difference in terms of seizure frequency for 6 months [22] . A retrospective study of 159 patients reported an increased frequency of seizures (≥30% of baseline frequency) in nine patients (6%) during the first 3 months after switching [23] . Among the patients who participated in this study, 66 patients were treated with LEV monotherapy. One patient increased seizure frequency and two patients decreased seizure frequency after generic substitution. To date, there has only been one study on generic substitution in LEV monotherapy. Twenty-eight patients with LEV monotherapy were switched to generic LEV; no increase in seizure frequency or adverse effects were observed [22] . These results indicate that generic substitution is generally safe in LEV monotherapy patients. Of the 82 LEV polytherapy patients in our study, the frequency of seizures increased in six patients and decreased in eight patients. The number of patients with increased or decreased seizure frequency was similar in LEV polytherapy patients; however, the change in seizure frequency was greater in LEV polytherapy patients than in LEV monotherapy patients. This may be because polytherapy is performed in patients with a high number of seizures; therefore, the number of seizures may vary in the polytherapy group.
The present study has several limitations. First, several confounding factors could contribute to a change in seizure frequency that mimics a breakthrough seizure. Second, the group sizes in this study may have been insufficient to show a significant effect. Third, patients with reluctance to take generics were rare, as we excluded people who refused to switch LEV. Indeed, the patients who refused generic substitution of LEV were prescribed LEV at other hospitals. Fourth, we did not perform blood monitoring for drugs, although the relationship between LEV serum concentration and its clinical effect has not been fully established [33] . Fifth, this study cannot be generalized to patients with poorly controlled epilepsy, because participants in this study were mostly patients with well controlled epilepsy (seizure freedom rate 76.4%). Finally, the data is retrospective and based on a medical chart review, and may therefore lend itself to ascertainment bias.
Conclusion
This study suggests that the risk of increased seizure frequency following generic substitution of LEV was minimal. Although generic substitution of LEV was generally safe, larger prospective studies are required.
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